-
公开(公告)号:US10150952B2
公开(公告)日:2018-12-11
申请号:US15540690
申请日:2015-12-24
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor: Jurgen Haas , Julian Ihssen , Michael Thomas Kowarik , Torsten Franz Schwede , Linda Christiane Thöny-Meyer
Abstract: Described herein are oligosaccharyl transferases for use in N-glycosylating proteins of interest in vitro and in host cells. Methods for using such oligosaccharyl transferases, nucleic acids encoding such oligosaccharyl transferases, and host cells comprising such oligosaccharyl transferases are also provided herein. Glycoconjugates generated by using such oligosaccharyl transferases are also provided herein.
-
公开(公告)号:US20180339037A1
公开(公告)日:2018-11-29
申请号:US16018292
申请日:2018-06-26
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor: William Ripley Ballou , Emmanuel Jules Hanon
IPC: A61K39/145 , A61K39/12 , A61K39/39 , C12N7/00 , A61K39/00
Abstract: The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 μg HA or a low amount such as less than 15 μg HA.
-
公开(公告)号:US10113009B2
公开(公告)日:2018-10-30
申请号:US15150302
申请日:2016-05-09
Applicant: GlaxoSmithKline Biologicals SA
Inventor: Allan James Saul , Francesca Micoli
IPC: C08B37/00 , C07K16/12 , C07K16/44 , A61K39/112 , A61K39/095 , A61K39/02 , A61K39/385 , C07K14/34 , A61K47/64 , A61K39/00
Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5. The invention also provides polysaccharide-linker-carrier molecule conjugates and intermediate compounds obtained or obtainable by these processes.
-
公开(公告)号:US10105429B2
公开(公告)日:2018-10-23
申请号:US15369405
申请日:2016-12-05
Applicant: GlaxoSmithKline Biologicals SA
Inventor: Laura Serino , Mariagrazia Pizza
IPC: A61K39/108 , C07K14/245 , A61K39/00
Abstract: The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.
-
195.
公开(公告)号:US20180291026A1
公开(公告)日:2018-10-11
申请号:US15526345
申请日:2015-11-13
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor: Helene G. BAZIN-LEE , Yufeng LI
IPC: C07D473/18 , A61K31/52 , A61K31/522 , A61K39/39
CPC classification number: C07D473/18 , A61K31/52 , A61K31/522 , A61K39/39 , A61K2039/55511
Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
-
公开(公告)号:US20180273560A1
公开(公告)日:2018-09-27
申请号:US16060142
申请日:2016-12-12
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor: Helene G. BAZIN-LEE , Laura S. BESS , David A. JOHNSON
IPC: C07F9/6558 , C07F9/6561 , C07F9/10
Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.
-
公开(公告)号:US20180250375A1
公开(公告)日:2018-09-06
申请号:US15747671
申请日:2016-07-25
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor: Marie-Ange DEMOITIE , Marie-Noelle Renelle DONNER , Nadia OUAKED
CPC classification number: A61K39/04 , A61K9/0019 , A61K35/761 , A61K39/12 , A61K39/39 , A61K45/05 , A61K2039/5256 , A61K2039/545 , A61P31/06 , C07K14/005 , C07K14/35 , C12N7/00 , C12N15/85 , C12N15/86 , C12N2710/10321 , C12N2710/10341 , C12N2710/10343 , C12N2740/16234 , C12N2760/18534
Abstract: The present invention relates to methods for inducing an immune response, in particular methods for inducing an immune response against mycobacterial infections or disease comprising (i) at least one administration of a polypeptide Rv1196 related antigen and at least one administration of an adenovirus encoding a Rv1196 related antigen or (ii) at least one administration of a polypeptide Rv0125 related antigen and at least one administration of an adenovirus encoding a Rv0125 related antigen. Associated compositions, adenoviral constructs and polynucleotide sequences are also provided.
-
公开(公告)号:US20180243395A1
公开(公告)日:2018-08-30
申请号:US15962507
申请日:2018-04-25
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor: Paolo COSTANTINO
IPC: A61K39/095 , A61K9/00 , C07K14/22 , A61K39/00 , A61K39/385 , A61K39/29 , A61K39/12 , A61K39/116 , A61K39/102 , A61K39/02 , A61K39/09 , A61K39/08 , A61K39/05
Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises
-
公开(公告)号:US20180237476A1
公开(公告)日:2018-08-23
申请号:US15789074
申请日:2017-10-20
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor: Kurt SWANSON , Andrea CARFI
IPC: C07K14/005 , A61K39/12 , A61K39/155
CPC classification number: C07K14/005 , A61K39/12 , A61K39/155 , A61K2039/53 , C07K2319/735 , C12N2760/18522 , C12N2760/18534
Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.
-
公开(公告)号:US20180153983A1
公开(公告)日:2018-06-07
申请号:US15809524
申请日:2017-11-10
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor: Francesco BERTI , Paolo COSTANTINO , Maria Rosaria ROMANO
IPC: A61K39/385 , A61K47/64 , A61K39/085 , A61K39/00
Abstract: The invention provides a process for preparing a conjugate of a S.aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerising the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidising the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidised saccharide residue; and (c) coupling the oxidised saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.
-
-
-
-
-
-
-
-
-